Assistant Professor of Medicine, University Colorado
Oncology
Dr. Wells A. Messersmith, MD
|
|
Give Review
Wells A. Messersmith practices Oncology. He studied medicine at Harvard Medical School. Harvard Medical School is a top medical college. Harvard Medical School has a rank of 1 in research and a 12 in primary care He has 3 awards "America's Top Doctors", "America's Top Doctors for Cancer" and "CMS Meaningful Use Stage 1 Certification". Wells Messersmith is a published doctor and has 82 publications published. The lastest was: 'Direct ex vivo analysis of activated, Fas-sensitive autoreactive T cells in human autoimmune disease.' Wells Messersmith accepts all Medicare patients.
Publications
- Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer.
- Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal Cancer cell lines and patient derived xenografts.
- A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metast...
- Right to Try?
- A phase I first-in-human study of enoticumab (REGN421), a fully-human Delta-like ligand 4 (Dll4) monoclonal antibody in patients with advanced solid Tumors.
- A Phase I, dose-finding study in patients with advanced solid malignancies of the Oral γ-secretase inhibitor PF-03084014.
- Panitumumab in the treatment of colon Cancer: A biomarker dilemma.
- Potent antitumor activity of Cabozantinib, a c-MET and VEGFR2 Inhibitor, in a Colorectal Cancer Patient-derived Tumor Explant Model.
- An Improved High Yield Total Synthesis and Cytotoxicity Study of the Marine Alkaloid Neoamphimedine: An ATP-Competitive Inhibitor of Topoisomerase IIα and Potent Antic...
- Anti-ma2 paraneoplastic encephalitis in association with recurrent cervical Cancer.
- A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenoCarcinoma.
- A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid Tumors.
- Phase 1 study of Oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies.
- MetaAnalysis of Survival, Complications, and Imaging Response following Chemotherapy-based Transarterial Therapy in Patients with Unresectable Intrahepatic Cholangioca...
- Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer.
- Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical coloRectal explant model.
- A patient tumor transplant model of squamous cell Cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins.
- Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal Cancer.
- Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatoCellular carcinoma.
- The development of regorafenib and its current and potential future role in Cancer therapy.
- A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung Cancer.
- Biomarker-driven trial in metastatic pancreas Cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic Cancer.
- Dual Pharmacological Targeting of the MAP Kinase and PI3K/mTOR Pathway in Preclinical Models of Colorectal Cancer.
- Acetaldehyde and retinaldehyde-metabolizing enzymes in colon and pancreatic Cancers.
- Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon Cancer models.
- Oxaliplatin-induced neuropathy in colorectal Cancer.
- Development of novel targeted agents in the treatment of metastatic colorectal Cancer.
- Longitudinal assessment of oxaliplatin-induced neuropathy.
- Promising targets and drugs in development for colorectal Cancer.
- Current status of SRC inhibitors in solid tumor malignancies.
- Recurrent pancreatic adenoCarcinoma after pancreatic resection.
- Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal Cancer.
- A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic Cancer.
- Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid Tumors.
- A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas Cancer.
- Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal Cancer.
- Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal Cancer.
- New strategies in colorectal Cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinosi...
- ACR Appropriateness Criteria: rectal Cancer-metastatic disease at presentation.
- Novel agents in the treatment of metastatic colorectal Cancer.
- Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic Cancer.
- A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced Cancer.
- KRAS mutation: comparison of testing methods and tissue sampling techniques in colon Cancer.
- TNF-blockade in patients with advanced hormone refractory prostate Cancer.
- Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas Cancer xenografts.
- Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic Cancer.
- KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal Cancer.
- [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.
- KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal Cancer: practical application of patient selection.
- Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid Tumors.
- Targeting EGFR in colorectal Cancer.
- A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal Cancer.
- Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid Tumors.
- Pharmacogenetic pathway Analysis of docetaxel elimination.
- No time to waste: decreasing patient wait times for chemotherapy administration using automated prioritization in an oncology pharmacy system.
- Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid Tumors.
- Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic Cancer.
- Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid Tumors.
- Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies.
- Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal Cancer: another one or the one?
- Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid Tumors.
- Myeloid growth factors. Clinical practice guidelines in oncology.
- Assessment of celecoxib pharmacodynamics in pancreatic Cancer.
- Novel targets in solid Tumors: MEK inhibitors.
- Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours.
- Chemotherapy and regional therapy of hepatic coloRectal metastases: expert consensus statement.
- An in vivo platform for translational drug development in pancreatic Cancer.
- A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay.
- Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ABT-751, ABT-751 glucuronide, and ABT-751 sulfate in human plasma...
- The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatoCellular carcinoma.
- Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in Cancer patients.
- Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid Tumors.
- In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel Oral tubulin-interactive agent.
- Assessment of Epidermal Growth Factor Receptor (EGFR) signaling in paired colorectal Cancer and normal colon tissue samples using computer-aided immunohistochemical an...
- Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate dimethyl benzoylphenylurea (BPU) and its five metabolites in huma...
- Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
- Recent advances in the pharmacological treatment of colorectal Cancer.
- The prevalence and implications of incidental findings on ED abdominal CT scans.
- Direct ex vivo Analysis of activated, Fas-sensitive autoreactive T cells in human autoimmune disease.
- Conditions required for the measurement of nitric oxide synthase activity in a myenteric plexus/smooth muscle preparation from the rat ileum.
- Gamma delta T Cell receptor gene expression by muscle-infiltrating lymphocytes in the idiopathic inflammatory myopathies.
Schools
Harvard Medical School
Massachusetts General Hospital Program
Johns Hopkins University School of Medicine Program
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
Education
-
Johns Hopkins University -
Massachusetts General Hospital -
Harvard Medical School
Hospital
-
University of Colorado Hospital
Drug Facts
| NPI NUMBER | 1760431472 | |
| NPPES Provider LastName | MESSERSMITH | |
| NPPES Provider FirstName | WELLS | |
| NPPES Provider ZIPCode | 800452545 | |
| NPPES Provider State | CO | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 241.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 14.0 | |
| Percent Opioid Claims | 5.81 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1760431472 |
| Last Name Of The Provider | MESSERSMITH |
| First Name Of The Provider | WELLS |
| View All |
Similar Doctors
|
Dr. William T. Purcell, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Han Myint, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vu H. Nguyen, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Thomas W. Flaig, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jonathan A. Gutman, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. William E. Daniel, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Stephen Leong, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Colin D. Weekes, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Vibha T. Thomas, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Virginia Borges, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Antonio Jimeno, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Sami G. Diab, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. D Ross Camidge, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karl D. Lewis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael S. Guy, MD
This Doctor is OpenDoctor Recommended.
|